Clinician's Guide to Spinal Muscular Atrophy

Jump to:
Medical advisors icon

Meet our

Medical advisors

Edward Smith, M.D.

Edward Smith, MD

Melissa Wright, MD, PhD

SMA Disease Course: What to Expect and Monitor

Written by Margaret Anne Rockwood | Last updated July 6th, 2026
✅ Medically reviewed by Edward Smith, MD

 

The natural disease course of spinal muscular atrophy (SMA) is characterized by a progressive loss of lower motor neurons caused by a deficiency of survival motor neuron (SMN) protein.

Historically, the disease followed a relatively predictable pattern in which weakness gradually worsened over time, leading to loss of motor function, orthopedic complications, respiratory impairment, and, in severe cases, premature death.

Today, disease-modifying therapies (DMTs) have dramatically altered the syndrome’s natural course. Although the underlying genetic defect remains unchanged, early intervention can preserve motor neurons, improve motor development, and significantly extend survival. As a result, the disease course of SMA varies considerably depending on disease severity, timing of diagnosis, and access to treatment.

Early Progression and Motor Neuron Loss

The progression of SMA begins long before weakness becomes clinically apparent.

Evidence from animal models and human studies suggests that inadequate SMN protein disrupts the normal development and maintenance of motor neurons during fetal life and early infancy. Motor neurons may initially form but fail to establish or maintain stable connections with muscle fibers.

As motor neurons degenerate, muscles lose their nerve supply and gradually weaken and atrophy. Because motor neurons cannot be replaced once they are lost, the timing of intervention becomes critically important.

This developmental vulnerability helps explain why treatment initiated before symptoms develop often produces substantially better outcomes than treatment started after weakness is established.

Increased Weakness

Although disease severity varies among SMA types, several common patterns are observed.

Weakness is usually:

  • symmetric
  • predominantly proximal
  • more severe in the legs than the arms
  • associated with progressive muscle atrophy

As weakness progresses, patients may experience:

  • difficulty sitting, standing, or walking
  • loss of previously acquired motor skills
  • fatigue and reduced endurance
  • increasing dependence on assistive devices

The rate of progression is generally fastest in infancy and early childhood and slower in later-onset forms of SMA.

Orthopedic and Musculoskeletal Complications

Progressive muscle weakness affects skeletal development and posture.

Common complications include:

  • scoliosis
  • joint contractures
  • hip instability
  • osteopenia and osteoporosis
  • chronic pain

These complications may further impair mobility and quality of life. Early physical therapy, orthopedic monitoring, and appropriate supportive interventions help reduce long-term disability.

Respiratory Complications

Respiratory muscle weakness is one of the most important determinants of morbidity and mortality in SMA.

Weakness of the intercostal muscles and diaphragm impairs chest wall expansion and cough effectiveness, increasing the risk of respiratory infections and restrictive lung disease. Bulbar dysfunction may further increase the risk of aspiration.

In severe SMA, respiratory complications historically represented the leading cause of death.

Today, noninvasive ventilation, cough-assist devices, airway-clearance techniques, and the availability of DMTs have substantially improved respiratory outcomes.

SMA’s Natural Course – If Left Untreated

It’s important to recognize that before DMTs became available, the clinical course of SMA generally reflected the degree of SMN protein deficiency.

SMA Type 0 began before birth and represented the most severe end of the disease spectrum. Reduced fetal movement may be recognized during pregnancy, and affected infants typically present with profound weakness, hypotonia, respiratory failure, and feeding difficulties at birth. Without intensive supportive care, survival is usually measured in weeks or months.

SMA Type 1 traditionally presented before 6 months of age. Infants never achieved independent sitting and developed progressive weakness, swallowing difficulties, and respiratory failure. Before modern therapies, most children died or required permanent ventilatory support within the first 2 years of life.

In SMA Type 2, diagnosed children typically achieved independent sitting but never attained independent walking. Progressive weakness often resulted in scoliosis, contractures, respiratory compromise, and increasing dependence on mobility devices. Many survived into adulthood with appropriate respiratory and orthopedic care, but may have lost the ability to sit independently.

Patients with SMA Type 3 achieved independent ambulation but often experienced progressive proximal weakness, frequent falls, and eventual loss of walking ability later in life. Life expectancy was often near normal, although at risk of losing independent ambulation over time.

Individuals with adult-onset SMA (Type 4) typically followed a slowly progressive course characterized by mild proximal weakness and gradual functional decline. Life expectancy was generally normal.

How Disease-Modifying Therapies Have Changed the Disease Course

The introduction of nusinersen, risdiplam, and onasemnogene abeparvovec have fundamentally altered the expected progression of SMA. These therapies increase functional SMN protein levels through different mechanisms. Specifically, nusinersen and risdiplam modify SMN2 RNA splicing, increasing production of full-length SMN protein, while onasemnogene abeparvovec and onasemnogene abeparvovec-brve deliver a functional copy of the SMN1 gene through an adeno-associated viral vector (AAV9).

The greatest benefits occur when treatment begins before significant motor neuron loss has occurred. Infants identified through newborn screening and treated presymptomatically may achieve developmental milestones that would not have been expected in the natural history of SMA. Many acquire and maintain independent sitting, standing, and even walking.

Even when treatment is initiated later, DMTs may slow progression, preserve existing motor function, and improve quality of life.

What’s Next: SMA as a Syndrome

While the traditional classification system remains useful, the disease course of SMA is becoming increasingly difficult to predict using historical models alone.

Children who would previously have been classified as SMA Type 1 may now achieve milestones that overlap with Type 2 or Type 3 phenotypes. Similarly, many treated patients experience slower progression than would have been expected based on historical data.

As a result, clinicians are increasingly viewing SMA as a spectrum disorder rather than a collection of rigid categories.

More and more, physicians are considering several factors in a patient’s prognosis, including SMA type, SMN2 copy number, age at symptom onset, timing of treatment, baseline motor function, and respiratory involvement. Among these factors, the timing of treatment has become perhaps most important. Early diagnosis through newborn screening and rapid initiation of therapy can provide the greatest opportunity to preserve motor neurons and improve long-term outcomes.

Modern disease-modifying therapies are substantially altering the natural course of the disease, particularly when treatment begins before symptoms develop.

Sources